DAX Up Nearly 0.5% As Stocks Recover After Weak Start

The German DAX reversed early losses, climbing 0.45% to 23,987.13, as initial concerns over a U.S. government shutdown were offset by renewed sentiment following relief over tariffs and news of a new U.S. platform for discounted prescription drugs. Merck notably surged 6.5% following positive Phase 3 trial results for its drug WINREVAIR. Concurrently, Germany's September Manufacturing PMI saw a slight upward revision to 49.5, still indicating near-stagnant conditions, while Eurozone inflation accelerated to 2.2% in September, consistent with forecasts.

Analysis

The German DAX index demonstrated resilience, recovering from an early drop to 23,741.00 to climb 0.45% to 23,987.13. The turnaround was driven by a sentiment shift away from U.S. government shutdown concerns towards relief from U.S. tariff developments and news of a new drug-pricing platform. Company-specific catalysts were prominent, with Merck leading the gains with a 6.5% surge following positive Phase 3 trial results for its WINREVAIR drug. Broad-based strength was also evident in stocks like Brenntag and Siemens Energy, which rose over 2.5%, while notable decliners included Rheinmetall, down approximately 2.5%. This market optimism contrasts with a challenging macroeconomic picture. The HCOB Germany Manufacturing PMI, despite an upward revision to 49.5, still indicates a near-stagnant and weakening environment compared to the previous month's 49.8. Furthermore, Eurozone headline inflation accelerated to 2.2% in September, with core inflation holding firm at 2.3%, suggesting persistent price pressures that could complicate the outlook for corporate margins and monetary policy.

Key Decisions for Investors

• Investors should recognize the positive Phase 3 data for Merck's WINREVAIR as a significant idiosyncratic catalyst, warranting a re-evaluation of the company's biopharma pipeline valuation.
• Given the DAX rally is sentiment-driven and contrasts with weak German PMI data, it is prudent to favor companies with strong, company-specific growth drivers over broad, cyclical index exposure.
• The combination of accelerating Eurozone inflation and stagnant German manufacturing presents a stagflationary risk that warrants monitoring, as it could pressure corporate profit margins and influence future central bank policy.